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Abstract
Background: A prospective clinical trial was conducted to evaluate the feasibility of a novel approach to the treatment
of patients with high risk prostate cancer (HRPC) through the use of a nomogram to tailor radiotherapy target volumes.
Methods: Twenty seven subjects with HRPC were treated with a mildly hypofractionated radiotherapy regimen using
image-guided IMRT technique between Jun/2013-Jan/2015.
A set of validated prognostic factors were inputted into the Memorial-Sloan-Kettering Cancer Center (MSKCC) prostate
cancer nomogram to estimate risk of loco-regional spread (LRS). The nomogram risk estimates for extra-capsular
extension (ECE), seminal vesicles involvement (SVI), and pelvic lymph nodes involvement (LNI) were used to adapt
radiotherapy treatment volumes based on a risk threshold of ≥15 % in all cases. A planning guide was used to delineate
target volumes and organs at risk (OAR). Up to three dose levels were administered over 28 fractions; 70Gy for gross
disease in the prostate +/− seminal vesicles (2.5Gy/fraction), 61.6Gy for subclinical peri-prostatic disease (2.2Gy/fraction)
and 50.4Gy to pelvic nodes (1.8Gy/fraction).
Data regarding protocol adherence, nomogram use, radiotherapy dose distribution, and acute toxicity were collected.
Results:
Nomogram use
100 % of patients were treated for ECE, 88.9 % for SVI, and 70.4 % for LNI. The three areas at risk of LRS were
appropriately treated according to the study protocol in 98.8 % cases. The MSKCC nomogram estimates for LRS
differed significantly between the time of recruitment and analysis.
Contouring protocol compliance
Compliance with the trial contouring protocol for up to seven target volumes was 93.0 % (159/171). Compliance
with protocol for small bowel contouring was poor (59.3 %).
Dose constraints compliance
Compliance with dose constraints for target volumes was 97.4 % (191/196). Compliance with dose constraints for
OAR was 88.2 % (285/323).
Acute toxicity
There were no grade 3 acute toxicities observed. 20/27 (74.1 %) and 6/27 (22.2 %) patients experienced a grade 2
genitourinary and gastrointestinal toxicity respectively.
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Conclusions: We have demonstrated the feasibility of this novel risk-adapted radiation treatment protocol for
HRPC. This study has identified key learning points regarding this approach, including the importance of
standardization and updating of risk quantification tools, and the utility of an observer to verify their correct
use.
Trial registration: ClincialTrials.gov identifier NCT01418040.
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Background
Radiotherapy (RT) has been shown to independently im-
prove overall survival for men with high risk prostate
cancer (HRPC) managed with androgen deprivation
therapy (ADT) [1, 2]. The traditional approach to radio-
therapy for HRPC is to treat the prostate alone. How-
ever, there is extensive surgical pathological literature
demonstrating the risk of subclinical disease infiltration
of HRPC into pelvic lymph nodes (PLN), seminal vesi-
cles (SV), and in an extra-prostatic distribution [3–5].
With the increased uptake of intensity modulated radio-
therapy (IMRT), there is a potential opportunity to tailor
treatment to such areas at significant risk of loco-
regional spread (LRS) rather than managing all men with
HRPC in an identical manner. In other sub-sites, for ex-
ample in the treatment of mucosal squamous cell carcin-
oma of the head and neck (HNSCC), this treatment
approach has long been accepted as standard of care.
Uncertainty regarding the role of whole pelvis radio-
therapy (WPRT) in high risk prostate cancer is reflected
in various clinical guidelines, in which the elective treat-
ment of pelvic nodes is left up to the treating clinician’s
discretion [6, 7]. Two randomized controlled trials
(RTOG 9413 and GETUG-01) have failed to convin-
cingly demonstrate improvement in progression free sur-
vival with the use of WPRT versus prostate-only
treatment [8, 9], although later results from the RTOG
study show improved biochemical control in a subset of
patients receiving neo-adjuvant hormonal therapy. Rea-
sons for a lack of benefit from WPRT have been de-
scribed, including insufficient radiation dose, inadequate
coverage of at-risk nodes, and poorly targeted patient se-
lection [10, 11]. Despite the lack of level I evidence for
WPRT, this practice has been incorporated into the
standard treatment of HRPC in multiple practice-
defining randomized controlled trials (RCT) [12–14].
WPRT in this setting is not without its risks; there is
mixed evidence to suggest increased acute and late grade
3 gastrointestinal toxicity and decreased bowel quality of
life [8, 9, 15, 16]. Despite reductions in dose to critical
structures and late GI adverse effects achieved through
the use of IMRT over 3D-conformal RT [17, 18], WPRT
is still likely to result in increased toxicity compared to
treatment of the prostate alone. It is therefore important
to reserve the use of WPRT, and to a lesser extent irradi-
ation of the SV and peri-prostatic regions, for those pa-
tients that are most likely to experience improved
tumour control outcomes.
We conducted a prospective clinical trial to assess the
feasibility and tolerability of a hypofractionated radio-
therapy treatment protocol for HRPC that employed the
use of a widely accessible and externally validated online
nomogram to estimate risk of LRS and accordingly adapt
delineation of target volumes.
Methods
Study design and participants
This prospective phase two single institution study en-
rolled patients with high-risk prostate cancer for
18 months (Jan 2013-June 2014). Patients were eligible
for the study if they met the following inclusion criteria:
histologically confirmed adenocarcinoma of the prostate,
high risk disease (defined by any one of baseline
prostate-specific antigen (PSA) ≥ 20 μg/L, Gleason Score
(GS) 8–10 and/or clinical stage T3-T4), and conven-
tional staging imaging negative for distant metastases
(technetium-99 m whole body bone scan and CT of ab-
domen and pelvis). Exclusion criteria included: previous
pelvic radiotherapy, history of prior malignancy within
the last 5 years (excluding non-melanomatous skin can-
cers), Eastern Cooperative Oncology Group (ECOG)
performance status ≥ 2, or any contraindication to inser-
tion of intra-prostatic fiducial markers or planning MRI
prior to RT simulation. All patients were administered a
total of 18 months of ADT in the form of Leuprorelin
22.5 mg every 3 months.
All patients gave written informed consent. The study
was reviewed and approved by the Hunter and New
England Human Research Ethics Committee (HNEH-
REC Ref: 12/08/15/4.02). The trial was registered with
ClincialTrials.gov (identifier NCT01418040).
Nomogram use
A set of parameters (age, PSA, tumour GS, clinical stage
and percentage of positive biopsies) were inputted into
the Memorial-Sloan-Kettering Cancer Center (MSKCC)
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prostate cancer nomogram [19] prior to radiotherapy
and again at time of analysis to estimate risk of LRS.
The pre-RT nomogram risk estimates for extra-capsular
extension (ECE), seminal vesicles involvement (SVI), and
pelvic lymph nodes involvement (LNI) were used to
adapt radiotherapy treatment volumes based on a risk
threshold of ≥15 % in all cases.
Simulation and planning protocol
Radiotherapy commenced after 6 months of neo-
adjuvant ADT, in keeping with the results from the
TROG 96.01 randomised trial showing superiority of
this duration verses 3 months or no ADT [20]. Follow-
ing insertion of three intra-prostatic gold fiducials, all
patients underwent CT simulation (Aquilion LB TSX-
201A, Toshiba Medical Systems Corporation) in the su-
pine position with customized immobilization. Patients
were instructed to have a comfortably full bladder and
an empty rectum for simulation and treatment. A 3-tesla
non-contrast planning MRI scan (MAGNETOM Skyra,
Siemens) using 2 mm slices and T2 weighting was com-
pleted on the same day and co-registered with the simu-
lation CT by matching to the fiducial markers.
A standardized planning guide was developed and used
to direct contouring of target volumes and organs at risk
(OAR) on the CT and MRI imaging. Target volumes were
contoured as listed in Table 1. Elective irradiation of
extra-capsular disease extension, proximal seminal vesi-
cles, and/or pelvic lymph nodes was completed if the risk
of involvement of each respective region exceeded 15 %,
as estimated by the MSKCC nomogram.
The rectum, bladder, neck of femur, small bowel and
penile bulb were contoured as organs at risk (OAR). The
rectum was contoured as a solid organ from the ano-
rectal junction to the recto-sigmoid flexure. The entire
bladder was also contoured as a solid organ. The small
bowel was contoured as any visible small bowel as well
as peritoneal contents within 8 mm of the superior mar-
gin of the PTV. This volume was expanded 3 mm in all
directions to create a small bowel planning organ at risk
volume (PRV).
Radiotherapy technique
Radiotherapy was administered over 28 daily fractions,
given five fractions per week using an image-guided
dynamic IMRT technique. Pre-treatment image guid-
ance was conducted using matching of kilovoltage im-
aging to the three intra-prostatic gold fiducial
markers with a 1 mm action threshold for a transla-
tional shift. Extrapolating from the HNSCC literature,
and given the expectation of reduced clonogen dens-
ity in imaging-negative areas, reduced radiotherapy
dosing was administered to elective regions. Up to
three dose levels were treated in 28 fractions using a
simultaneous integrated boost:
 All patients received radiotherapy to the prostate +/−
seminal vesicles (if grossly involved on clinical
examination or MRI) to a dose of 70 Gy (2.5 Gy per
fraction).
 If the nomogram estimate for ECE ≥15 %, an
additional volume (formed by a 3 mm isotropic
expansion from the prostate excluding overlap
with the rectum) was treated to 61.6 Gy (2.2 Gy
per fraction).
 If the nomogram estimate for SVI ≥15 %, the
proximal 20 mm of the seminal vesicles was treated
to 61.6 Gy (2.2 Gy per fraction).
 If the nomogram estimate for LNI ≥15 %, the
pelvic lymph nodes were treated to 50.4 Gy
(1.8 Gy per fraction), contoured according to
RTOG consensus guidelines [21] with a modified
upper border of 10 mm inferior to the sacral
promontory.
Table 1 Contouring protocol for target volumes
Structure Contouring protocol Condition
CTVP Prostate as defined using CT and MRI imaging + any extra-prostatic extension as noted on examination or pre-ADT
imaging
All patients
CTVECE 3 mm isotropic margin from CTVP, excluding overlap with rectum If ECE risk≥ 15 %
CTVSVI Entire bilateral seminal vesicles (only contoured if known seminal vesicle involvement) If SV involved
CTVSVA Proximal 20 mm of SV, measured obliquely along long axis of SV (only contoured for adjuvant treatment of
seminal vesicles)
If SVI risk≥ 15 %
CTVLN Pelvic nodes: 7 mm margin around obturator, pre-sacral, and external and internal iliac vessels contoured as per
RTOG consensus guidelines [21], up to 10 mm inferior to the sacral promontory)
If LNI risk≥ 15 %
PTV70 If no SV involvement: 5 mm margin around CTVP If SV involvement: 5 mm margin around CTVP + 7 mm margin
around CTVSVI anteriorly and posteriorly and 5 mm otherwise
All patients
PTV61.6 If SV involvement or SVI risk <15 %: 5 mm margin around CTVECE If no SV involvement and SVI risk ≥15 %: 5 mm
margin around CTVECE + 7 mm margin around CTVSVA anteriorly and posteriorly and 5 mm otherwise
If CTVECE or CTVSVA
contoured
PTV50.4 5 mm margin around CTVLN If CTVLN contoured
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Dose constraints
Planning objectives and field arrangement were opti-
mized to achieve the best dosimetry to satisfy dose con-
straints for target volumes and OAR (listed in Table 2).
All planning was performed using the Eclipse Treatment
Planning System v12 (Varian Medical Systems). In par-
ticular, dosing to the PTVs aimed to deliver 100 % of the
prescribed dose to 98 % of the target volume as per
ICRU 83 [22].
Data collection and analysis
Genitourinary and gastrointestinal toxicity were assessed
on a weekly basis during radiotherapy, at 1.5 months
and 4.5 months post radiotherapy, then at 6 monthly in-
tervals thereafter. Scoring of toxicity was completed
using the Radiation Therapy Oncology Group (RTOG)
acute and late radiation morbidity scoring criteria.
Efficacy of treatment will be assessed by biochemical
no evidence of disease (bNED) as defined by the ASTRO
Phoenix definition (nadir + 2.0 mcg/L) [23]. bNED was
and will be assessed at each post-RT review. Treatment
efficacy outcome results will be presented at a later date
when longer follow-up has been achieved.
Evaluation of compliance with the trial protocol for
nomogram-directed target volume delineation, contour-
ing, and dose constraints were conducted after the final
patient completed radiotherapy. To demonstrate feasibil-
ity, we aimed to achieve ≥90 % protocol compliance rate
with each of these parameters.
Up to seven target structures (CTVP, CTVECE,
CTVSVA/SVI, CTVLN, PTV70, PTV61.6, and PTV50.4)
were generated for each patient according to the proto-
col outlined in Table 1. At the time of analysis, each pa-
tient’s plan was reviewed to determine whether
appropriate target structures were treated according to
the threshold of ≥15 % risk of involvement as estimated
by the MSKCC nomogram. Each target structure was
assessed for strict adherence to the contouring protocol
by a third party not involved in the original planning
process (RW). This assessment was repeated for con-
touring of OAR.
Dose constraints for target volumes and OAR were
assessed according to the objectives listed in Table 2.
Values exceeding the ‘mandatory’ limits were termed
‘major variations’. Values in between the ‘mandatory’
and ‘ideal’ limits were termed ‘minor variations’. In all
cases, descriptive statistics generated from Microsoft
Excel are presented.
Sub-studies examining the use of imaging to predict
risk of ADT-induced loss of bone mineral density, and
the prognostic significance of circulating tumour cells
were completed concurrently using the same patient co-
hort and are reported on separately [24, 25].
Results
Patient characteristics
Twenty eight patients were enrolled onto the trial, of
which 27 (96.4 %) completed the planned treatment
without unscheduled breaks. The remaining patient was
not suitable for treatment due to an acute myocardial in-
farction prior to radiotherapy. Two patients were en-
rolled to the trial despite baseline characteristics not
fulfilling the inclusion criteria for high risk disease. Me-
dian follow-up at the time of analysis was 11.4 months.
The patient characteristics are shown in Table 3.
Nomogram use and radiotherapy treatment volumes
The MSKCC nomogram was used to estimate risk of loco-
regional spread (ECE, SVI and LNI) both prior to radio-
therapy (to direct treatment), and later at the time of data
analysis. There was a difference in nomogram outputs be-
tween these two time points (Table 4). Student’s t-test
demonstrated significant increases for ECE and LNI (both
p < 0.001), but no change for SVI (p = 0.35). If current
nomogram outputs were used instead of those obtained
prior to RT, 9 of 27 patients would have received different
treatment; seven patients using larger volumes and two pa-
tients using smaller volumes.
Radiotherapy target volumes were expanded to ac-
count for risk of ECE in 27/27 patients (100 %), SVI in
Table 2 Dose constraints for target volumes and organs at risk
Target volumes Mandatory Ideal
PTV70 D98% ≥70.0 Gy -
PTV70 D1cc ≤77.0 Gy ≤74.9 Gy
PTV61.6 D98% ≥61.6 Gy -
PTV50.4 D98% ≥50.4 Gy -
CTVP ≥70.0 Gy -
CTVSVI D99% ≥70.0 Gy -
CTVECE D99% ≥61.6 Gy -
CTVLN D99% ≥50.4 Gy -
Organs at risk
Rectum D15% ≤74.0 Gy ≤74.0 Gy
Rectum D25% ≤69.0 Gy ≤60.0 Gy
Rectum D35% ≤64.0 Gy ≤50.0 Gy
Rectum D50% ≤59.0 Gy ≤40.0 Gy
Bladder D15% ≤79.0 Gy ≤74.0 Gy
Bladder D25% ≤74.0 Gy ≤60.0 Gy
Bladder D30% ≤69.0 Gy ≤50.0 Gy
Bladder D50% ≤64.0 Gy ≤40.0 Gy
Neck of femur D5% ≤44.0 Gy -
Small bowel PRV D99% ≤52.0 Gy -
Small bowel V45Gy ≤195 cc -
Penile bulb mean dose - ≤51.0 Gy
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24/27 (88.9 %), and LNI in 19/27 (70.4 %). An example
of the volumes treated to three different dose levels is
shown in Fig. 1. Areas at risk of LRS were appropriately
included/omitted from treatment according to the study
protocol in 98.8 % of cases. However, error in inputting
post-ADT rather than pre-ADT PSA into the nomogram
for two patients resulted in falsely low estimates of LRS,
and the incorrect omission of treatment of both SV and
PLN.
Contouring of target volumes and OAR
The seven target volumes were correctly delineated ac-
cording to the trial contouring protocol in 94.1 % of
cases (160/170). Compliance with protocol for contour-
ing of OAR (rectum, bladder, small bowel) was 70.4 %
(57/81), although 22/24 variations were due to small
bowel contouring that was incorrect or omitted.
Dose constraints
Each patient’s radiotherapy plan was assessed for adher-
ence to 5–8 target volume dose constraints and up to 13
Table 3 Baseline patient characteristics
Median (range)
Age 70.6 years (54.6–78.9)
PSA 12.4 ng/mL (4.0–52.1)
% biopsy cores positive 50 % (25–100)
Gleason Score Number of patients (percentage)
3 + 4 2 (7 %)
4 + 3 3 (11 %)
4 + 4 3 (11 %)
4 + 5 16 (59 %)
5 + 4 4 (15 %)
T stage Number of patients (percentage)
T1b 1 (4 %)
T1c 3 (11 %)
T2a 1 (4 %)
T2b 7 (25 %)
T2c 4 (14 %)
T3a 9 (32 %)
T3b 3 (11 %)
Table 4 Nomogram estimates for risk of LRS at pre-radiotherapy
and at time of data analysis
Pre-RT At analysis Paired t-test
ECE 70.7 % (20.8) 87.1 % (13.8) p < 0.001
SVI 47.0 % (24.1) 43.5 % (24.7) p = 0.356
LNI 32.05 % (27.7) 50.4 % (26.9) p < 0.001
Data is presented as mean (standard deviation)
Two patients with known pelvic lymph node metastases were entered as
100 % risk of LNI
Fig. 1 Typical radiotherapy dose distribution. Legend: PTV70 (yellow),
PTV61.6 (cyan) and PTV50.4 (dark blue) are displayed with dose colour
wash overlay
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OAR dose constraints, dependent upon the volumes
treated. Compliance with dose constraints for target vol-
umes was 97.1 % (170/175), with 1.7 % minor variations
and 1.1 % major variations. Compliance with dose con-
straints for OAR was 88.2 % (285/323), with 9.9 % minor
variations and 1.9 % major variations.
Acute toxicity
There was no grade ≥3 genitourinary (GU) or gastro-
intestinal (GI) acute toxicity observed (Table 5). 20/27
(74.1 %) patients experienced grade 2 GU toxicity at
some point during radiotherapy. In all cases this was ei-
ther increased obstructive or irritative urinary symptoms
managed with supportive measures such as Tamsulosin
or urinary alkalinisation respectively. 6/27 (22.2 %) pa-
tients experienced grade 2 GI toxicity in the form of in-
creased bowel frequency managed with Loperamide.
Discussion
We have demonstrated the feasibility of a risk-adjusted
radiotherapy treatment protocol that adapts target vol-
ume delineation based on nomogram estimates of risk of
LRS. This treatment was shown to be technically feas-
ible, clinically practicable, and resulted in acceptable
levels of acute toxicity in line with standard of care.
It is important to appreciate the natural patterns of
spread of disease when determining target volumes to be
treated. A rich surgical pathological literature is available
to inform this approach, demonstrating the frequency,
and often extent of disease involvement. For example,
the risk of SV involvement in patients with T2 disease
has been described, as has the fact that in 90 % of such
cases disease is confined to the proximal 20 mm of the
SV measured along the axis of the structure [4]. It is per-
haps noteworthy that in the HNSCC setting, such data
regarding pathological risk of loco-regional involvement
is deemed appropriate to allow clinical implementation
without prospective clinical trial validation [26]. Yet in
the prostate radiotherapy setting, clinical trials attempt-
ing to quantify the benefit of WPRT continue to be per-
formed (e.g. RTOG 0534 and RTOG 0924). In the era of
improved imaging, integration of new systemic agents,
and highly conformal radiotherapy, it will be challenging
for such studies to definitively answer such questions for
all patients, which is part of the reason that most mod-
ern protocols simply mandate the extent of elective vol-
ume treatment [27].
The twenty-eight treatment hypofractionated radio-
therapy regimen used in this study was first described by
the Cleveland Clinic [28]. This original protocol has
been adapted to form the experimental arm in the
RTOG 0415 study, a multi-centre phase III randomized
controlled trial examining modest hypofractionation for
treatment of favourable risk prostate cancer. Neither of
these treatment regimens included elective WPRT. Two
separate groups in the US have published their experi-
ences administering conventionally fractionated WPRT
concurrently or sequentially with hypofractionated pros-
tate irradiation [16, 29]. Early data regarding biochemical
control and toxicity from these four groups have demon-
strated encouraging results with the modestly hypofrac-
tionated treatment.
The frequency of grade ≥2 acute GU toxicity (74.1 %)
observed in this trial was slightly higher than that re-
corded by the aforementioned studies of McDonald et al.
(52 %) and Pollack et al. (approximately 56 %) [16, 29].
This difference may be accounted for by the increased
dose to the seminal vesicles (61.6 Gy vs. 56 Gy or 50 Gy
respectively) or more likely, a lower threshold for the use
of interventions. The increase in toxicity was limited in se-
verity to RTOG grade 2, and it remains to be seen whether
this will translate into more meaningful differences in late
toxicity. The absence of grade 3 acute toxicity in this study
is reassuring and consistent with the published data using
similar treatments. The incidence of grade ≥2 acute GI
toxicity (22.2 %) was in the same range as the levels seen
in the University of Alabama at Birmingham series (37 %)
[16]. Their series treated all HRPC men with the same
radiotherapy doses to the primary disease and pelvic
lymph nodes as in our cohort, and have reported efficacy
and late toxicity rates similar to conventional treatment.
Our data adds to the literature that supports the feasibility
of moderately hypofractionated radiotherapy treating the
prostate and pelvis concurrently for men with HRPC.
The question remains as to how best to select patients
for radiotherapy volume adaptation. Some guidelines
such as from the EORTC recommend using the D’Amico
risk stratification. This would probably lead to overtreat-
ment, as some patients designated as high risk actually
have very favourable outcomes, illustrating the hetero-
geneity of such risk groupings [30]. Clinical tools such
as the ‘Partin tables’ [31] have analysed historical data
from large cohorts of patients undergoing radical prosta-
tectomy to demonstrate the correlation between LRS
and prognostic factors such as PSA, GS, and clinical sta-
ging. This data could provide an individualized estimate
for risk and degree of LRS, which may then be used to
adapt the extent of treatment. The use of a web-based
nomogram (such as the MSKCC nomogram) allows fur-
ther refinements to this approach. The clinical tool is
widely accessible, simple to use, considers the additional
Table 5 Maximal acute toxicity (during radiotherapy)
Grade 0 Grade 1 Grade 2 ≥ Grade 3
Genitourinary 2 (7.4 %) 5 (18.5 %) 20 (74.1 %) 0 (0 %)
Gastrointestinal 12 (44.4 %) 9 (33.3 %) 6 (22.2 %) 0 (0 %)
Data is presented as number of patients (% of total cohort)
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variable of tumour volume, and considers relevant prog-
nostic factors as continuous rather than discrete variables.
Furthermore, as the calculations are not completed manu-
ally, the underlying algorithm can be sufficiently complex
to achieve maximal accuracy. For these reasons, a
computer-based nomogram is a powerful tool that facili-
tates risk-adapted treatment individualization.
There are, however, a number of limitations in using a
nomogram in this fashion. First of all, the nomogram is
dependent upon historical data that may not be suitable for
extrapolation to the current population. Changes in disease
epidemiology, staging, and screening practices mean that
the effect of prognostic factors may differ between contem-
porary and historical populations, and the estimates may
therefore be inaccurate. A key example of this was the up-
ward migration of Gleason scoring in recent years, partly
due to the altered definitions of the core biopsy grading sys-
tem introduced in 2005 [32]. There is therefore a need to
regularly review the applicability of historical results to
current populations and update the nomogram algorithms
accordingly (which then also prompts the need for external
re-validation). The degree to which this affects results is il-
lustrated in the difference in nomogram outputs between
the time of planning and analysis (Table 4).
Secondly, most clinical tools used to estimate the risk
of LRS in prostate cancer are based upon radical prosta-
tectomy series that employed limited lymph node dissec-
tion. It has been demonstrated that standard/limited
pelvic lymph node dissections may result in false nega-
tive rates for pathological involved nodes of over 50 %
compared to extended dissections [33]. Nomogram algo-
rithms that have been derived from this data may there-
fore generate estimates of LNI that are deceptively low.
Thirdly, there is a danger that data entry errors may
result in grossly inaccurate estimates of LRS and incor-
rect clinical decision-making. For example, a misplaced
decimal point, or inputting the post-ADT PSA rather
than PSA at diagnosis may alter the nomogram esti-
mates considerably. The latter error occurred twice in
our study and resulted in artificially low estimates of
LRS and incorrect non-treatment of seminal vesicles and
pelvic nodes in these patients. Simple safeguards would
prevent such errors from occurring, for example, an ob-
server to verify correct data entry and nomogram use.
Fourthly, there are small sub-groups of prostate cancer
patients who are not suitable for nomogram-directed adap-
tation of treatment. Outcomes for PSA-negative tumours
for example are not correctly predicted with current nomo-
grams. This group however represents only a very select
subset of patients (1 % or less of total prostate cancer cases)
who very often present late with metastatic disease that is
not suitable for curative treatment [34]. Neuroendocrine
carcinoma of the prostate is another group for which stand-
ard prognostic tools are similarly unsuitable.
A further lesson from our experience was appreciating
the danger in over-complicating treatment. The novel
treatment regimen used in this study involves a number
of features that increase its complexity compared to
standard practice. These include the use of a nomogram
to define risk of LRS and adapt target delineation, proto-
colised generation of multiple target structures to be
treated using up to three different dose levels, and a
hypofractionated regimen with many unfamiliar dose
constraints. Added complexity is liable to increase the
likelihood of errors and protocol non-compliance and
must be justified with a benefit to clinical outcomes. We
identified a number of examples of this, including rota-
tion of the simulation CT images to contour the prox-
imal seminal vesicles along their axes, or the use of
multiple, redundant dose constraints for rectum and
bladder. Here, excessive and unfamiliar processes are
unlikely to improve outcomes and should be simplified.
If additional complexity is value-adding, it may be neces-
sary to implement further safeguards such as peer review
of contouring and the use of checklists to maximise
protocol compliance.
We have demonstrated feasibility and deliverability of
a complex risk-adapted treatment for patients with
HRPC. Many future directions are being pursued along
similar lines. The use of more extreme hypofractionation
coupled with pelvic radiotherapy is increasing, for ex-
ample in the ‘SATURN’ trial, in which stereotactic radio-
therapy treatment is administered over 5 fractions to
both the prostate and pelvic lymph nodes. A similar
protocol used in the earlier ‘FASTR’ trial however re-
sulted in unacceptable levels of late toxicity, suggesting
caution in using such an approach [35].
In contrast, emerging imaging modalities such as PSMA
PET are likely to detect early metastatic spread with in-
creased sensitivity, which may reduce the number of at-risk
patients with negative staging investigations who are there-
fore candidates for elective loco-regional treatment. If this
does eventuate, however, we would then face the question
of how to treat this growing group of patients with early
loco-regional or oligometastatic disease, an area where
there is again a paucity of evidence to guide management.
It is likely that the management of prostate cancer will shift
further towards a risk-adapted approach as the results of
current trials and integration of new imaging into clinical
practice continues.
Conclusions
We have demonstrated the feasibility of this novel risk-
adapted radiation treatment protocol for HRPC. This study
has identified key learning points regarding this approach,
including the importance of standardization and updating
of risk quantification tools, and the utility of an observer to
verify their correct use.
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